ubiquinone and Cytokine-Release-Syndrome

ubiquinone has been researched along with Cytokine-Release-Syndrome* in 2 studies

Reviews

1 review(s) available for ubiquinone and Cytokine-Release-Syndrome

ArticleYear
Age-related mitochondrial dysfunction as a key factor in COVID-19 disease.
    Experimental gerontology, 2020, Volume: 142

    SARS-CoV-2 causes a severe pneumonia (COVID-19) that affects essentially elderly people. In COVID-19, macrophage infiltration into the lung causes a rapid and intense cytokine storm leading finally to a multi-organ failure and death. Comorbidities such as metabolic syndrome, obesity, type 2 diabetes, lung and cardiovascular diseases, all of them age-associated diseases, increase the severity and lethality of COVID-19. Mitochondrial dysfunction is one of the hallmarks of aging and COVID-19 risk factors. Dysfunctional mitochondria is associated with defective immunological response to viral infections and chronic inflammation. This review discuss how mitochondrial dysfunction is associated with defective immune response in aging and different age-related diseases, and with many of the comorbidities associated with poor prognosis in the progression of COVID-19. We suggest here that chronic inflammation caused by mitochondrial dysfunction is responsible of the explosive release of inflammatory cytokines causing severe pneumonia, multi-organ failure and finally death in COVID-19 patients. Preventive treatments based on therapies improving mitochondrial turnover, dynamics and activity would be essential to protect against COVID-19 severity.

    Topics: Aging; Animals; COVID-19; Cytokine Release Syndrome; Humans; Inflammation; Mitochondria; SARS-CoV-2; Ubiquinone

2020

Other Studies

1 other study(ies) available for ubiquinone and Cytokine-Release-Syndrome

ArticleYear
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Protein & cell, 2020, Volume: 11, Issue:10

    Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Dihydroorotate Dehydrogenase; Drug Evaluation, Preclinical; Gene Knockout Techniques; Humans; Hydroxybutyrates; Influenza A virus; Leflunomide; Mice; Mice, Inbred BALB C; Nitriles; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Protein Binding; Pyrimidines; RNA Viruses; SARS-CoV-2; Structure-Activity Relationship; Thiazoles; Toluidines; Ubiquinone; Virus Replication

2020